Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Isoflurane 100%
Baxter Healthcare Ltd
Isoflurane 100%
100 %
Volatile liquid for inhalation
Active: Isoflurane 100%
Bottle, glass, 1x100ml, 100 mL
Prescription
Prescription
Baxter Healthcare of Puerto Rico
AERRANE is a volatile halogenated anaesthetic for general inhalation anaesthesia.
Package - Contents - Shelf Life: Bottle, glass, - 100 mL - 60 months from date of manufacture stored at or below 30°C - Bottle, glass, - 250 mL - 60 months from date of manufacture stored at or below 30°C
1993-12-24
NEW ZEALAND DATA SHEET AERRANE Data Sheet 4 March 2019 Page 1 of 13 Baxter Healthcare Ltd 1 AERRANE INHALATION ANAESTHETIC (100% volatile liquid for inhalation) AERRANE INHALATION ANAESTHETIC, 100%, volatile liquid for inhalation. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Isoflurane 100% (USP) (1mL/mL). 3 PHARMACEUTICAL FORM Volatile liquid for inhalation. Isoflurane is a clear, colourless, stable volatile liquid containing no additives or chemical stabilisers; it has a mildly pungent, musty, ethereal odour. Isoflurane does not decompose in the presence of soda lime, and does not attack aluminium, tin, brass, iron or copper. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications AERRANE is a volatile halogenated anaesthetic for general inhalation anaesthesia. 4.2 Dose and method of administration AERRANE INHALATION ANAESTHETIC should be administered only by persons trained in the administration of general anaesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. In order to be able to accurately control the precise concentration of AERRANE INHALATION ANAESTHETIC, vaporisers that have been specially designed and calibrated for isoflurane should be used. Dosage for induction and maintenance must be individualized and titrated to the desired effect according to the patient’s age and clinical status. With the exception of neonates, the minimum alveolar concentration (MAC) of isoflurane decreases with increasing patient age. Minimum alveolar concentration (MAC) of AERRANE INHALATION ANAESTHETIC in humans: Age O 2 100% O 2 + N 2 O (60%) Neonates 1.60 – 1 – 6 months 1.87 – 7 – 11 months 1.80 – 1 – 2 years 1.60 – 3 – 5 years 1.62 – 6 – 10 years 1.40 0.58 10 – 15 years 1.16 0.53 Age O 2 100% O 2 + N 2 O (70%) 26 ± 4 years 1.28 0.56 44 ± 7 years 1.15 0.50 64 ± 5 years 1.05 0.37 _ _ _ _ NEW ZEALAND DATA SHEET AERRANE Data Sheet 4 March 2019 Page 2 of 13 Baxter Healthcare Ltd _Induction of anaesth Read the complete document